Clinical trial
A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.
NCT04049266 is registered in ClinicalTrials.gov with Kodiak Sciences Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.
- Lead sponsor
- Kodiak Sciences Inc
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- October 8, 2019
- Completion date
- April 26, 2022
- Enrollment
- 559 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.